Close
Nordic 9Nordic 9

BVCF Management (investor - Private Equity)

China bvcf.com
See something wrong or missing? Let us know
Offices:Shanghai

BVCF Management, formally known as BioVeda China Fund, is a growth capital focused private equity fund specializing in China Life Sciences and Healthcare.

Average round investment:57M USD
Average number per year:1.0
Distribution: 2021 (1)
Portfolio companies: Iceland Oculis Pharma
Mostly invests in: Iceland Iceland (1) Pharma (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to BVCF Management

Name Criteria
United States Pivotal bioVenture Partners
60%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Common investees countries: Iceland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Bay City Capital
60%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Common investees countries: Iceland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Venrock Healthcare Capital Partners
56%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Foresite Capital
56%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Viking Global Investors
56%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Cormorant Asset Management
56%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States venBio Partners
56%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Denmark Axcel
54%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
China GT Healthcare Capital
53%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Evotec AG
53%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top